Why The Legend Biotech LEGN Story Is Shifting As Carvykti And Competition Reframe Expectations [Yahoo! Finance]
Legend Biotech Corporation - American Depositary Shares (LEGN)
Company Research
Source: Yahoo! Finance
discount rate moving to 7.20% from 7.18% as analysts revisit their assumptions. These small changes come alongside fresh coverage and target updates that focus on how Carvykti adoption, competitive therapies, and execution could influence the long term revenue narrative for the company. Stay tuned to see how you can keep on top of these kinds of incremental, but meaningful, narrative shifts as they emerge. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Legend Biotech. ?? Bullish Takeaways Oppenheimer recently initiated coverage with an Outperform rating and a US$75 price target, pointing to Carvykti as a core asset and highlighting its current commercial presence in multiple myeloma. The firm argues Legend Biotech screens as the most undervalued among 11 peers they track, even as Carvykti sales stand out compared with other CAR T therapies across indications. Oppenheimer acknowledges competitive pressures
Show less
Read more
Impact Snapshot
Event Time:
LEGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEGN alerts
High impacting Legend Biotech Corporation - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
LEGN
News
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) [Yahoo! Finance]Yahoo! Finance
- Legend Biotech (NASDAQ:LEGN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $75.00 price target on the stock.MarketBeat
- Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical OfficerGlobeNewswire
LEGN
Sec Filings
- 1/14/26 - Form 6-K
- 1/12/26 - Form 6-K
- 12/29/25 - Form 144
- LEGN's page on the SEC website